| | Business Summary | | Inkine
Pharmaceutical
Company,
Inc.,
formerly
Panax
Pharmaceutical
Company,
Ltd.,
is
a
biopharmaceutical
company.
The
Company
initially
focused
on
the
development
of
new
pharmaceutical
compounds
identified
in
and
isolated
from
plants.
In
early
1996,
the
Company
modified
its
strategy,
reducing
its
natural
product
discovery
activities
and
redirecting
its
principal
efforts
toward
expanding
its
pipeline
of
commercially
viable
pharmaceutical
products
by
licensing
or
acquiring
specifically
targeted
products
developed
for
the
treatment
of
certain
diseases. | | More
from
Market Guide: Expanded
Business Description |
| | Financial Summary | | InKine
is
a
biopharmaceutical
company
focused
on
the
diagnosis
and
treatment
of
cancer
and
autoimmune
diseases;
and
acquires
late-stage
drug
candidates
with
short
time
lines
to
commercialization.
For
the
comparable
six
months
ended
6/30/01,
revenues
totaled
$3.4
million,
up
from
$0.
Net
loss
rose
63%
to
$6.1
million.
Results
reflect
sales
of
Visicol
(TM)
to
pharmaceutical
wholesalers
and
large
drug
store
chains,
offset
by
higher
personnel-related
and
marketing
expenses. | | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Leonard Jacob, M.D., Ph.D., 52
Chairman
of Directors and CEO | $675K | -- | Martin Rose, M.D., 54
Exec.
VP of R&D | 330K | $384K | Robert Apple, 34
Sr.
VP and CFO | 533K | 452K | James Bergey, Ph.D., 54
Sr.
VP, Bus. Devel. | 114K | -- | | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors:
Expanded
List, Bios,
Compensation,
Options
|
|
![[one-year price graph]](http://chart.yahoo.com/c/0b/i/inkp.gif)